Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) had its target price increased by equities researchers at Robert W. Baird from $40.00 to $52.00 in a report released on Monday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Robert W. Baird's target price indicates a potential upside of 137.33% from the stock's current price.
Other equities research analysts have also recently issued reports about the stock. HC Wainwright boosted their price objective on shares of Enliven Therapeutics from $39.00 to $40.00 and gave the company a "buy" rating in a research report on Thursday, May 15th. Jones Trading reduced their price objective on Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating for the company in a research report on Friday, May 16th. Finally, The Goldman Sachs Group initiated coverage on Enliven Therapeutics in a research report on Monday. They set a "buy" rating and a $37.00 price target for the company. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $39.60.
Check Out Our Latest Analysis on ELVN
Enliven Therapeutics Price Performance
NASDAQ ELVN opened at $21.91 on Monday. Enliven Therapeutics has a one year low of $13.30 and a one year high of $30.03. The firm has a market cap of $1.08 billion, a P/E ratio of -11.53 and a beta of 0.79. The stock's 50-day moving average is $18.30 and its 200-day moving average is $20.60.
Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.06). Equities analysts anticipate that Enliven Therapeutics will post -1.95 EPS for the current year.
Insider Transactions at Enliven Therapeutics
In related news, insider Joseph P. Lyssikatos sold 12,500 shares of the business's stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $20.61, for a total transaction of $257,625.00. Following the transaction, the insider now directly owns 1,002,688 shares in the company, valued at approximately $20,665,399.68. The trade was a 1.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Anish Patel sold 6,667 shares of the company's stock in a transaction on Monday, June 9th. The stock was sold at an average price of $20.34, for a total transaction of $135,606.78. Following the sale, the chief operating officer now directly owns 303,309 shares in the company, valued at $6,169,305.06. This trade represents a 2.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 88,611 shares of company stock worth $1,676,289 in the last three months. Insiders own 25.90% of the company's stock.
Hedge Funds Weigh In On Enliven Therapeutics
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. Rhumbline Advisers grew its holdings in Enliven Therapeutics by 4.9% in the 1st quarter. Rhumbline Advisers now owns 52,502 shares of the company's stock valued at $1,033,000 after buying an additional 2,466 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of Enliven Therapeutics during the first quarter worth $578,000. Goldman Sachs Group Inc. boosted its stake in shares of Enliven Therapeutics by 61.3% during the first quarter. Goldman Sachs Group Inc. now owns 211,752 shares of the company's stock valued at $4,167,000 after purchasing an additional 80,506 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Enliven Therapeutics by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company's stock worth $428,000 after buying an additional 1,693 shares during the period. Finally, Ally Bridge Group NY LLC grew its stake in shares of Enliven Therapeutics by 19.8% in the first quarter. Ally Bridge Group NY LLC now owns 169,774 shares of the company's stock worth $3,341,000 after purchasing an additional 28,064 shares during the last quarter. 95.08% of the stock is owned by institutional investors.
Enliven Therapeutics Company Profile
(
Get Free Report)
Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enliven Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enliven Therapeutics wasn't on the list.
While Enliven Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
